Skip to content
Biodatica
Start free

Investigator

Michael G Agadjanyan

INSTITUTE FOR MOLECULAR MEDICINE · funded by NIA

Companies
3

Resolved onto their grants.

Grants
4

Federal awards on file.

Non-dilutive funding
$12M

Summed across those awards.

First award
Feb 15, 2022

Latest Aug 1, 2025.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R01

    FDA approved IND 29644: Multicenter Phase 1 Trial to Evaluate Safety and Immunogenicity of Preventive Tau Vaccine, AV-1980R/A, in cognitively unimpaired preclinical AD participants.

    $5.3M

    Aug 1, 2025NIAINSTITUTE FOR MOLECULAR MEDICINENIH RePORTER · 11108959 (opens the source filing in a new tab)

  2. U01

    IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)

    $1.8M

    Jun 5, 2024NIAINSTITUTE FOR MOLECULAR MEDICINENIH RePORTER · 11103129 (opens the source filing in a new tab)

  3. R01

    Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.

    $2.3M

    Feb 15, 2022NIAINSTITUTE FOR MOLECULAR MEDICINENIH RePORTER · 11053526 (opens the source filing in a new tab)

  4. R01

    Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.

    $2.1M

    Feb 15, 2022NIAINSTITUTE FOR MOLECULAR MEDICINENIH RePORTER · 11300264 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources